Epidemiology of hematological malignancies
2007; Elsevier BV; Volume: 18; Linguagem: Inglês
10.1093/annonc/mdl443
ISSN1569-8041
AutoresDelvys Rodríguez‐Abreu, Andrea Bordoni, Emanuele Zucca,
Tópico(s)Chronic Lymphocytic Leukemia Research
ResumoHematological malignancies comprise a collection of heterogeneous conditions, all originating from cells of the bone marrow and the lymphatic system. There are three major groups: leukemia, lymphoma, and plasma cell neoplasms. In general, in Western countries the overall incidence of hematological malignancies appears to be rising but it is very difficult to describe in a consistent and uniform way their epidemiological behavior, especially in Europe. The number of European Union (EU) Member States has increased and this expansion enlarged the Union to incorporate a diversity of peoples with a much larger degree of heterogeneity in lifestyle habits and disease risk, as well as in cancer incidence and mortality (either overall or site-specific). Moreover, there is not a unique European reporting system or registry for hematological cancers, so the estimation of the exact number of patients is difficult. In addition, the comparison of the incidences reported by various European registries may be biased because their populations can be predominantly either urban or rural, or because there are differences in the methodology and accuracy of registration. The number of new patients in Europe diagnosed with hematological malignancies in 2005 can be estimated in 230 000 patients. These new cases of leukemia, Hodgkin’s and non-Hodgkin’s lymphoma (NHL) and myeloma account for 8% of all the new cancer patients diagnosed in Europe and the estimated deaths from these tumors account for 7% of the cancer-related deaths in 2005. Incidence rates for the main hematological cancers in Europe and the United States are summarized in Tables 1 and 2.
Referência(s)